诺沃·诺迪斯克以4.7B美元购买Akero治疗药物,以推进肝病药物Efruxifermin。 Novo Nordisk to buy Akero Therapeutics for $4.7B to advance liver disease drug efruxifermin.

Novo Nordisk同意以47亿美元的现金购买Akero治疗药物, 如果Akero的药物候选者Efruxifermin得到美国批准, Novo Nordisk has agreed to acquire Akero Therapeutics for $4.7 billion in cash, with an additional potential $500 million in contingent payments if efruxifermin, Akero’s drug candidate, receives U.S. approval for treating compensated cirrhosis due to MASH, a severe liver condition linked to metabolic dysfunction. 这笔交易预计将在2026年初结束, 加强了Novo Nordisk对除糖尿病和肥胖症以外的新陈代谢和肝脏疾病的关注。 The deal, expected to close in early 2026, strengthens Novo Nordisk’s focus on metabolic and liver diseases beyond diabetes and obesity. Efruxifermin,一种21类纤维增殖因子,处于第3阶段试验阶段,显示出扭转肝纤维化的希望。 Efruxifermin, a fibroblast growth factor 21 analogue, is in Phase 3 trials and has shown promise in reversing liver fibrosis. Akero的股价在市场前贸易中上涨了近20%。 Akero’s shares rose nearly 20% in premarket trading. 这种收购不会影响Novo Nordisk2025年的利润前景,但可能会减少自由的现金流动,增加2026年的研发成本。 The acquisition will not affect Novo Nordisk’s 2025 profit outlook but may reduce free cash flow and increase R&D costs in 2026.